跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
SANDOZ EFAVIRENZ/EMTRICITABINE/TENOFOVIR - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
SANDOZ EFAVIRENZ/EMTRICITABINE/TENOFOVIR
Authorized
STANDARD
SANDOZ EFAVIRENZ/EMTRICITABINE/TENOFOVIR
Sandoz Canada, Inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
f3151b0a9bbf5a11
Company
Sandoz Canada, Inc.
Type
Standard
Approval Details
Approval Id
f3151b0a9bbf5a11
Drug Approval Canada Name
SANDOZ EFAVIRENZ/EMTRICITABINE/TENOFOVIR
Product Name
SANDOZ EFAVIRENZ/EMTRICITABINE/TENOFOVIR
Status
Cancelled Post Market
Status Date
2022-05-12
Original Market Date
2019-09-30
Din
02484676
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
08:18.08.20
Atc Original
J05AR06 EMTRICITABINE, TENOFOVIR DISOPROXIL AND EFAVIRENZ
Atc Name
j 05 ar 06
Aig Number
0352327001
Company Name
Sandoz Canada, Inc.
Company Address
4600 Rue Armand-Frappier, Saint-Hubert, Quebec, Canada, J3Z 1G5
Company Detail Path
/organization/sandoz-canada-inc
Company Information
Pharmaceutical Company Name
Sandoz Canada, Inc.
Country Name
Canada
Website
http://www.sandoz.ca
Active Ingredients
TENOFOVIR DISOPROXIL FUMARATE
300 MG
EFAVIRENZ
600 MG
EMTRICITABINE
200 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
f3151b0a9bbf5a11
Type
Standard
Back to Health Canada Approvals